The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately. The price has jumped 53% in a year, to $6.28 per unit — sharp rises like this often mean supply is already tightening.
Market view
pancrelipase · Capsule, Delayed Release Pellets
28 marketed package NDCs · 3 active manufacturers
Most dispensed: AMYLASE 60000 [USP'U]; LIPASE 12000 [USP'U]; PROTEASE 38000 [USP'U] · Capsule, Delayed Release Pellets · #100 capsule, delayed release pellets/bottle · LIPASE 24000 [USP'U]; PROTEASE 76000 [USP'U]; AMYLASE 120000 [USP'U] · Capsule, Delayed Release Pellets · #100 capsule, delayed release pellets/bottle · LIPASE 36000 [USP'U]; AMYLASE 180000 [USP'U]; PROTEASE 114000 [USP'U] · Capsule, Delayed Release Pellets · #100 capsule, delayed release pellets/bottle · AMYLASE 30000 [USP'U]; LIPASE 6000 [USP'U]; PROTEASE 19000 [USP'U] · Capsule, Delayed Release Pellets · #1 bottle/carton / 100 capsule, delayed release pellets in 1 bottle
Price range and competition
RSS: changes for this drugEvery company selling this drug reports its own price. The line follows the middle of the pack; the shaded band holds the middle half of companies — the wider it is, the more they disagree.
Latest · Sep 2026 — typical price $6.28 · middle half $3.68–$9.43 · full range $2.11–$12.69 · 8 products · 3 companies
ⓘ How this was built
Data sources
- CMS NADAC weekly survey + monthly archives back to 2013 (data.medicaid.gov)
- CMS Federal Upper Limit files (weighted AMP)
- FDA NDC Directory (openFDA) — maker roster
Method
Each month's band spans the NADAC unit prices of every NDC of this drug (min, quartiles, median, max), split into brand and generic cohorts by FDA marketing category. Maker counts come from distinct labelers with the NDC actively listed.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
What changed in the last 90 days
Every detected change for pancrelipase, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
- ViokaceSep 2, 2026Mfr exitedAimmune Therapeutics, Inc. · pancrelipase
- ViokaceSep 2, 2026Mfr exitedAimmune Therapeutics, Inc. · pancrelipase
- PancrelipaseSep 2, 2026Mfr exitedAbbott Laboratories GmbH · pancrelipase
- PancrelipaseSep 2, 2026Mfr exitedAbbott Laboratories GmbH · pancrelipase
- PancrelipaseSep 2, 2026Mfr exitedAbbott Laboratories GmbH · pancrelipase
- PancrelipaseSep 2, 2026Mfr exitedAbbott Laboratories GmbH · pancrelipase
- PancrelipaseSep 2, 2026Mfr exitedAbbott Laboratories GmbH · pancrelipase
- PertzyeSep 2, 2026Mfr exitedDigestive Care, Inc. · pancrelipase
- PertzyeSep 2, 2026Mfr exitedDigestive Care, Inc. · pancrelipase
- PertzyeSep 2, 2026Mfr exitedDigestive Care, Inc. · pancrelipase
Common questions
- Is Pancrelipase in shortage right now?
- No. FDA does not currently list Pancrelipase in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Pancrelipase?
- 8 companies have marketed Pancrelipase in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.
- What does Pancrelipase cost?
- The typical pharmacy pays about $4.21 per unit, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.